<DOC>
	<DOC>NCT02274233</DOC>
	<brief_summary>The purpose of this study is to assess safety and amount of the study drug in the blood after increasing doses of SP-420. The study will be conducted in patients with β-thalassemia.</brief_summary>
	<brief_title>Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>Subject has ironoverload secondary to βthalassemia requiring chronic red blood cell transfusions and iron chelation therapy Subject weighs ≥35 kg Subject is willing to discontinue current iron chelation therapy at least 7 days prior to the first dose of SP420 and for the duration of the study Serum ferritin ≥700 ng/mL and iron saturation ≥70% within 3 weeks before Baseline (Day 1) Cardiac T2* score &gt;20 msec within 6 months before Baseline (Day 1) Willing to use contraception during the study Pregnant or breastfeeding Serum creatinine greater than the upper limit of normal Platelet count &lt;100 × 10^9/L Use of another investigational drug within the last 30 days Significant cardiac, renal, hepatic dysfunction or other clinically significant conditions that, in the opinion of the Investigator, would exclude the subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Chelation</keyword>
	<keyword>Iron Overload</keyword>
	<keyword>Thalassemia</keyword>
	<keyword>Transfusion</keyword>
	<keyword>Iron Chelation</keyword>
</DOC>